Literature DB >> 17900301

A role for T cell-derived interleukin 22 in psoriatic skin inflammation.

K Boniface1, E Guignouard, N Pedretti, M Garcia, A Delwail, F-X Bernard, F Nau, G Guillet, G Dagregorio, H Yssel, J-C Lecron, F Morel.   

Abstract

Interleukin (IL)-22 is a T cell-derived cytokine that has been reported recently to induce cutaneous inflammation in an experimental murine model of psoriasis, and to induce in vitro an inflammatory-like phenotype. In the present study, we assessed the presence of IL-22 and the IL-22 receptor 1 (IL-22R1) in skin lesions, skin-derived T cells, as well as IL-22 levels in sera from patients with psoriasis. IL-22R1 and IL-10R2 transcripts are expressed at a similar level in psoriatic and healthy skin. In contrast, IL-22 mRNA expression was up-regulated in psoriatic skin lesions compared to normal skin, whereas IL-22 mRNA levels in peripheral blood mononuclear cells from psoriatic patients and normal subjects were similar. Circulating IL-22 levels were significantly higher in psoriatic patients than in normal subjects. T cells isolated from psoriatic skin produced higher levels of IL-22 in comparison to peripheral T cells isolated from the same patients. IL-10 was expressed at similar levels in skin biopsies and peripheral blood mononuclear cells of psoriatic patients and normal subjects. Finally, we show here that supernatants of lesional psoriatic skin-infiltrating T cells induce an inflammatory response by normal human epidermal keratinocytes, resembling that observed in psoriatic lesions. Taken together, the results reported in this study indicate that IL-22 is a cytokine produced by skin-infiltrating lymphocytes that is potentially involved in initiation and/or maintenance of the pathogenesis of psoriasis.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17900301      PMCID: PMC2219373          DOI: 10.1111/j.1365-2249.2007.03511.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  38 in total

1.  Identification of the functional interleukin-22 (IL-22) receptor complex: the IL-10R2 chain (IL-10Rbeta ) is a common chain of both the IL-10 and IL-22 (IL-10-related T cell-derived inducible factor, IL-TIF) receptor complexes.

Authors:  S V Kotenko; L S Izotova; O V Mirochnitchenko; E Esterova; H Dickensheets; R P Donnelly; S Pestka
Journal:  J Biol Chem       Date:  2000-10-16       Impact factor: 5.157

2.  Cloning and characterization of IL-10-related T cell-derived inducible factor (IL-TIF), a novel cytokine structurally related to IL-10 and inducible by IL-9.

Authors:  L Dumoutier; J Louahed; J C Renauld
Journal:  J Immunol       Date:  2000-02-15       Impact factor: 5.422

3.  Cracking the cytokine code in psoriasis.

Authors:  Brian J Nickoloff
Journal:  Nat Med       Date:  2007-03       Impact factor: 53.440

4.  Interleukin (IL)-22, a novel human cytokine that signals through the interferon receptor-related proteins CRF2-4 and IL-22R.

Authors:  M H Xie; S Aggarwal; W H Ho; J Foster; Z Zhang; J Stinson; W I Wood; A D Goddard; A L Gurney
Journal:  J Biol Chem       Date:  2000-10-06       Impact factor: 5.157

5.  Oncostatin M secreted by skin infiltrating T lymphocytes is a potent keratinocyte activator involved in skin inflammation.

Authors:  Katia Boniface; Caroline Diveu; Franck Morel; Nathalie Pedretti; Josy Froger; Elisa Ravon; Martine Garcia; Emilie Venereau; Laurence Preisser; Emmanuel Guignouard; Gérard Guillet; Guy Dagregorio; Jérôme Pène; Jean-Pierre Moles; Hans Yssel; Sylvie Chevalier; François-Xavier Bernard; Hugues Gascan; Jean-Claude Lecron
Journal:  J Immunol       Date:  2007-04-01       Impact factor: 5.422

6.  Cloning and characterization of IL-22 binding protein, a natural antagonist of IL-10-related T cell-derived inducible factor/IL-22.

Authors:  L Dumoutier; D Lejeune; D Colau; J C Renauld
Journal:  J Immunol       Date:  2001-06-15       Impact factor: 5.422

7.  Identification, cloning, and characterization of a novel soluble receptor that binds IL-22 and neutralizes its activity.

Authors:  S V Kotenko; L S Izotova; O V Mirochnitchenko; E Esterova; H Dickensheets; R P Donnelly; S Pestka
Journal:  J Immunol       Date:  2001-06-15       Impact factor: 5.422

8.  Human interleukin-10-related T cell-derived inducible factor: molecular cloning and functional characterization as an hepatocyte-stimulating factor.

Authors:  L Dumoutier; E Van Roost; D Colau; J C Renauld
Journal:  Proc Natl Acad Sci U S A       Date:  2000-08-29       Impact factor: 11.205

9.  A soluble class II cytokine receptor, IL-22RA2, is a naturally occurring IL-22 antagonist.

Authors:  W Xu; S R Presnell; J Parrish-Novak; W Kindsvogel; S Jaspers; Z Chen; S R Dillon; Z Gao; T Gilbert; K Madden; S Schlutsmeyer; L Yao; T E Whitmore; Y Chandrasekher; F J Grant; M Maurer; L Jelinek; H Storey; T Brender; A Hammond; S Topouzis; C H Clegg; D C Foster
Journal:  Proc Natl Acad Sci U S A       Date:  2001-07-31       Impact factor: 11.205

10.  Response of psoriasis to interleukin-10 is associated with suppression of cutaneous type 1 inflammation, downregulation of the epidermal interleukin-8/CXCR2 pathway and normalization of keratinocyte maturation.

Authors:  K Reich; C Garbe; V Blaschke; C Maurer; P Middel; G Westphal; U Lippert; C Neumann
Journal:  J Invest Dermatol       Date:  2001-02       Impact factor: 8.551

View more
  110 in total

Review 1.  Structure and function of interleukin-22 and other members of the interleukin-10 family.

Authors:  Daniela Barretto Barbosa Trivella; José Ribamar Ferreira-Júnior; Laure Dumoutier; Jean-Christophe Renauld; Igor Polikarpov
Journal:  Cell Mol Life Sci       Date:  2010-05-08       Impact factor: 9.261

Review 2.  New insights in the immunologic basis of psoriasis.

Authors:  Kristine E Nograles; Batya Davidovici; James G Krueger
Journal:  Semin Cutan Med Surg       Date:  2010-03

Review 3.  Cytokine-receptor interactions as drug targets.

Authors:  Gideon Schreiber; Mark R Walter
Journal:  Curr Opin Chem Biol       Date:  2010-07-07       Impact factor: 8.822

4.  Inhibition of TYK2 and JAK1 ameliorates imiquimod-induced psoriasis-like dermatitis by inhibiting IL-22 and the IL-23/IL-17 axis.

Authors:  Melissa G Works; Fangfang Yin; Catherine C Yin; Ying Yiu; Kenneth Shew; Thanh-Thuy Tran; Nahoko Dunlap; Jennifer Lam; Tim Mitchell; John Reader; Paul L Stein; Annalisa D'Andrea
Journal:  J Immunol       Date:  2014-08-25       Impact factor: 5.422

5.  Norepinephrine and adenosine-5'-triphosphate synergize in inducing IL-6 production by human dermal microvascular endothelial cells.

Authors:  Lori L Stohl; Julie B Zang; Wanhong Ding; Michela Manni; Xi K Zhou; Richard D Granstein
Journal:  Cytokine       Date:  2013-09-08       Impact factor: 3.861

Review 6.  Regulation and function of proinflammatory TH17 cells.

Authors:  Gustavo J Martinez; Roza I Nurieva; Xuexian O Yang; Chen Dong
Journal:  Ann N Y Acad Sci       Date:  2008-11       Impact factor: 5.691

7.  Cyclosporine A immunosuppression drives catastrophic squamous cell carcinoma through IL-22.

Authors:  Melody Abikhair; Hiroshi Mitsui; Valerie Yanofsky; Nazanin Roudiani; Channa Ovits; Teddy Bryan; Tatiana M Oberyszyn; Kathleen L Tober; Juana Gonzalez; James G Krueger; Diane Felsen; John A Carucci
Journal:  JCI Insight       Date:  2016-06-02

8.  In vitro-differentiated TH17 cells mediate lethal acute graft-versus-host disease with severe cutaneous and pulmonary pathologic manifestations.

Authors:  Michael J Carlson; Michelle L West; James M Coghill; Angela Panoskaltsis-Mortari; Bruce R Blazar; Jonathan S Serody
Journal:  Blood       Date:  2008-10-28       Impact factor: 22.113

9.  IL-22 is essential for lung epithelial repair following influenza infection.

Authors:  Derek A Pociask; Erich V Scheller; Sivanarayana Mandalapu; Kevin J McHugh; Richard I Enelow; Cheryl L Fattman; Jay K Kolls; John F Alcorn
Journal:  Am J Pathol       Date:  2013-03-11       Impact factor: 4.307

Review 10.  IL-22 in tissue-protective therapy.

Authors:  Heiko Mühl; Patrick Scheiermann; Malte Bachmann; Lorena Härdle; Anika Heinrichs; Josef Pfeilschifter
Journal:  Br J Pharmacol       Date:  2013-06       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.